Keyphrases
3-group
16%
Adjusted Hazard Ratio
16%
Adjusted Model
16%
Alemtuzumab
50%
Analysis Support
16%
Antithymocyte Globulin
100%
Cold Ischemia
16%
Composite Graft
16%
Confidence Interval
16%
Cox Proportion Hazard Model
16%
Diabetes Type 1
16%
Dialysis
16%
Donor Risk Index
16%
Graft Loss
16%
Graft Outcome
16%
Graft Survival
66%
HLA Matching
16%
Induction Agents
100%
Induction Regimen
16%
Induction Type
66%
Interleukin-2 Receptor Antagonist
50%
Kaplan-Meier Survival
16%
Kidney
16%
Kidney Graft
33%
Kidney Graft Survival
16%
Kidney Transplant Recipients
16%
Kidney Transplant Rejection
16%
Multivariable Model
16%
Non-associated
16%
Pancreas
16%
Pancreas Donor
16%
Pancreas Graft
16%
Pancreas Graft Survival
16%
Panel-reactive Antibody
16%
Recipient Age
16%
Recipient Survival
33%
Rejection Rate
33%
Scientific Registry of Transplant Recipients
16%
Simultaneous Pancreas-kidney
66%
Simultaneous Pancreas-kidney Transplant
100%
Steroid Maintenance
16%
Survival Function
16%
United States
100%
Univariable Analysis
16%
Medicine and Dentistry
Alemtuzumab
50%
Anesthesia Induction
100%
Composite Graft
16%
Diabetes
16%
Graft Failure
16%
Graft Survival
83%
Hazard Ratio
16%
Interleukin 2 Receptor
50%
Ischemia
16%
Kidney Graft
33%
Kidney Graft Rejection
16%
Kidney Pancreas Transplantation
100%
Pancreas Transplantation
33%
Panel Reactive Antibody
16%
Receptor Antagonist
50%
Thymocyte Antibody
100%
Transplantation
16%
Pharmacology, Toxicology and Pharmaceutical Science
Alemtuzumab
50%
Graft Failure
16%
Interleukin 2 Receptor
50%
Ischemia
16%
Kidney Graft Rejection
16%
Leporidae
100%
Panel Reactive Antibody
16%
Receptor Antagonist
50%
Thymocyte Antibody
100%
Immunology and Microbiology
Alemtuzumab
37%
Anti-Thymocyte Globulin
75%
Cold Ischemia
12%
Interleukin 2 Receptor
37%
Kidney Graft Rejection
12%
Leporidae
75%
Pancreas
100%
Pancreas Transplantation
25%
Panel Reactive Antibody
12%